SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 2

Evaluation of Castration-Resistant Elderly Patients

Ahmet ÖZVEREN
Ferhat EKİNCİ
Gülcan BULUT
Serkan YILDIRIM
Atike Pınar ERDOĞAN
Pages
251–255
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The primary endpoint of the study was determined as overall survival time.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: In the present time suggesting an extended human lifespan and expectancy, elderly patients receive asignificant portion of daily healthcare practice whereas they have not been sufficiently addressed in the extensiveand comprehensive clinical studies.
📊
Key Findings & Data:We have desgined our study to evaluate the treatment options in this metastaticcastration-resistant prostate cancer patients older than 70 years.
💡
Conclusion & Impact:The primary endpoint of the study was determined as overall survival time.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: In the present time suggesting an extended human lifespan and expectancy, elderly patients receive asignificant portion of daily healthcare practice whereas they have not been sufficiently addressed in the extensiveand comprehensive clinical studies. We have desgined our study to evaluate the treatment options in this metastaticcastration-resistant prostate cancer patients older than 70 years. Methods: Our study is retrospective. The data of the patients from 5 centers of Turkey were obtained. The patients aged70 years and over were assigned to a group (geriatric group) while the rest of the patients were evaluated in anothergroup (normal group). The primary endpoint of the study was determined as overall survival time. Results: Totally 113 patients were included in our study. The geriatric and normal groups included 58 and 55 patients,respectively. Overall survival as the primary endpoint of our study demonstrated no statistically significant differencebetween survival of the patients aged over 70 years and other patients (geriatric group versus normal group, respectively 18.86 versus 23.93 months, respectively, p=0,542). Progresion-free survival as the secondary endpoint; no statistically significant difference was detected between two groups (geriatric group vs normal group, median 7.83 vs 8.5months, respectively, p=0.73). Conclusion: It was detected that the age variable has a negative impact on overall survival of prostate cancer cases.The overall survival was found numerically shorter in the patients aged 70 years and over set as age limit, however, thisdifference was not found statistically significant.

🔖

Cite This Article

ÖZVEREN, A., EKİNCİ, F., BULUT, G., YILDIRIM, S., ERDOĞAN, A. P. (2022). Evaluation of Castration-Resistant Elderly Patients. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 2, 251–255. https://ajindex.com/articles/508556

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. SEER Cancer Statistics Review, 1975-2006, Horner MJ, Ries LAG, Krapcho M, et al, editors. National Cancer Institute, Bethesda. Based on November 2008 SEER data submission, posted t o the SEER web site 2009. Avaialable at: https://seer. cancer.gov/csr/1975_2006/ (Accessed on July 26, 2019)
  2. National Cancer Institute. SEER Cancer Stat Facts: Prostate cancer. Available at: https://seer.cancer.gov/statfacts/html/ prost.html (Accessed on July 24, 2019
  3. Droz JP, Albrand G, Gillessen S, Hughes S, Mottet N, Oudard S, et al. Management of prostate cancer in elderly patients: recommendations of a task force of the international society of geriatric oncology. Eur Urol 2017;72:521-31
  4. Grummet JP, Plass K, N'Dow J. Prostate cancer management in an ageing Population. Eur Urol 2017;72:532–33
  5. Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 2019;116:116-36
  6. Ferrell BR, Temel JS, Temin S, Smith TJ. Integration of palliative care into standard oncology care: ASCO clinical practice guideline update summary. J Oncol Pract 2017;13:119–21
  7. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al; American Society of Clinical Oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007;25:1596–605
  8. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013;368:1314–25
  9. Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36:1080–7
  10. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al; LATITUDE Investigators. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Can cer. N Engl J Med 2017;377:352–60
  11. Landre T, Guetz GD, Chouahnia K, Fossey-Diaz V, Taleb C, Culine S. Is there a benefit of addition docetaxel, abiraterone, celecoxib, or zoledronic acid in initial treatments for patients older than 70 years with hormone-sensitive advanced prostate cancer? A meta-analysis. Clin Genitourin Cancer 20